Basecamp Research Raises $140M for AI-Designed Therapies

Basecamp Research has raised a $140M Series C to move its EDEN biological foundation models deeper into medicine development. S32 led the oversubscribed financing, with NVIDIA, Anthropic's Anthology Fund, Catalio Capital Management, NATO Innovation Fund, The Rockefeller Foundation, Singular, True Ventures, and other investors participating.

The round was announced on September 23, 2026. Reuters reported that the financing valued the London company at $800M. Basecamp Research says the capital will train a new EDEN generation, advance six AI-designed therapeutic programs toward clinical development, and expand pharmaceutical partnerships.

The important shift is from model capability to development responsibility. Basecamp Research has spent years assembling proprietary biological context. The Series C gives it more room to discover whether that information can survive the long handoff from data to model, model to therapeutic candidate, and candidate to evidence that matters in medicine.

What Happened

Basecamp Research's official announcement names S32 as lead investor. The syndicate also includes European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, PostScriptum, Redalpine, Sovereign AI, and senior industry figures including Roche Vice-Chairman André Hoffmann.

The company previously raised a $60M Series B in October 2024 led by Singular and a $20M Series A in December 2022. Those 3 disclosed rounds total $220M. Public sources disagree about whether other early capital should be included, so a broader total is not treated as settled.

The financing also changes the operating bench. Richard Pearce, formerly of Biogen, has joined as CBO to expand pharmaceutical partnerships. Andy Conrad, a General Partner at S32 and former CEO of Verily, is joining the board.

From Biodiversity Data to Therapeutic Design

Co-founders Glen Gowers and Oliver Vince started Basecamp Research in 2019 around a gap in biological AI: much of life's genetic diversity is missing from the datasets used to train models. The company built scientific and biodiversity partnerships across more than 30 countries and all seven continents to assemble proprietary evolutionary context.

Basecamp Research now describes its Trillion Gene Atlas as the world's largest proprietary biological AI training dataset. Its current website reports more than 100B novel genes and more than 100T tokens. Those figures are company-reported, but the strategic logic is clear. If biological model performance depends on the range and context of training data, owning a wider data supply chain can become a defensible part of the therapeutic platform.

EDEN is the model layer built on that foundation. Basecamp Research says its 28B-parameter model can translate evolutionary data into therapeutic candidates across gene insertion, gene editing, and peptide design. NVIDIA separately identifies Basecamp Research as a BioNeMo ecosystem model builder and notes EDEN's work on large-DNA-segment insertion.

Why In Vivo Cell Therapy Matters

Basecamp Research plans to begin with in vivo cell therapy, which means reprogramming a patient's cells inside the body. Many existing cell-therapy workflows remove cells, engineer them outside the patient, manufacture the treatment, and then return the cells. Basecamp Research says that process can cost hundreds of thousands of dollars per patient.

Its proposed approach combines long DNA sequences designed by EDEN with large serine recombinases intended to integrate those sequences precisely into the genome. If the platform works as intended, in vivo delivery could make cell therapies more programmable and simpler to administer while supporting more complex genetic instructions.

That promise still sits on the preclinical side of the ledger. Basecamp Research reports strong preclinical results across multiple modalities and disease areas, and its website describes six programs. Reuters noted that the company has not provided a clinical-trial start date. No patient outcomes have been disclosed.

The $140M Translation Test

AI drug discovery has no shortage of models that can produce a plausible candidate. Medicine development asks different questions. Can the candidate be manufactured, delivered, measured, reproduced, and defended in front of regulators? Can a partnership survive the years and capital required to generate clinical evidence? Can a platform choose the right programs instead of proving that it can generate many interesting ones?

Basecamp Research has assembled a leadership team for that translation. Glen Gowers is co-founder and CEO. Oliver Vince remains co-founder. Phil Lorenz is CTO, John Finn is CSO, and Richard Pearce now leads business development and partnerships as CBO. The scientific platform, therapeutic-development experience, and commercial handoff now have named owners.

The investor group adds another layer of intent. S32, NVIDIA, Anthology Fund, NATO Innovation Fund, The Rockefeller Foundation, and returning life-sciences investors are backing more than a model-training exercise. They are financing a vertically integrated attempt to connect biodiversity partnerships, proprietary data, foundation models, therapeutic design, and preclinical programs.

What This Signals for AI-Designed Medicine

The competitive question in biological AI is moving beyond parameter counts. Proprietary data can matter, but so can the provenance, diversity, and economic relationships behind that data. Basecamp Research's access-and-benefit-sharing structure is part of the business model because it helps determine whether unique biological information can be collected responsibly and used repeatedly.

The next competitive boundary is translation. Model builders that move into therapeutics inherit the economics and timelines of drug development. They also gain the chance to capture more value if the platform produces programs that pharmaceutical partners or the company itself can advance.

Basecamp Research's $140M Series C is large enough to make that strategy visible. The company has financial room, a six-program pipeline, new commercial leadership, and an incoming board member with healthcare and data experience. The evidence will now arrive program by program, through preclinical packages, partnership decisions, regulatory milestones, and eventually clinical data.

EDEN was trained to recognize patterns across a wider record of life. Basecamp Research now has to show that those patterns can become instructions precise enough for medicine to trust.